Teflaro (ceftaroline fosamil; Actavis/AstraZeneca/Dainippon Sumitomo Pharma) is a fifth-generation cephalosporin. The highly water-soluble prodrug ceftaroline fosamil is quickly converted in the blood to the active agent ceftaroline upon administration. The drug targets penicillin-binding proteins on susceptible bacterial strains. It inhibits bacterial cell wall synthesis, reduces the integrity of the bacterial cell wall, and ultimately causes cell death. Teflaro is active against a wide range of Gram-positive bacterial strains including Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus agalactiae. It also has activity against some Gram-negative strains including E. coli, Klebsiella pneumonia, and Klebsiella oxytoca. Furthermore, the drug has also demonstrated bactericidal activity against some multidrug-resistant bacterial strains including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate Staphylococcus aureus, as well as Zyvox-resistant and Cubicin-non-susceptible strains, but it is not effective against extended-spectrum beta-lactamase-producing Gram-negative bacteria. Teflaro’s activity against MRSA stems from its ability to bind to a penicillin-binding protein specific to this bacterial strain called the PBP2a.
LIST OF FIGURES
8 Figure 1: Phase III data for Teflaro in the treatment of community-acquired pneumonia in
9 Figure 2: Teflaro for community-acquired pneumonia – SWOT analysis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Teflaro in communityacquired
11 Figure 4: Datamonitor Healthcare’s drug assessment summary of Teflaro in communityacquired
20 Figure 5: Teflaro – SWOT analysis in cSSSI
22 Figure 6: Datamonitor Healthcare’s drug assessment summary of Teflaro in cSSSI
22 Figure 7: Datamonitor Healthcare’s drug assessment summary for Teflaro in cSSSI
LIST OF TABLES
4 Table 1: Teflaro drug profile
6 Table 2: Overview of pivotal trial data for Teflaro in community-acquired pneumonia
16 Table 3: Teflaro’s drug profile in cSSSI
18 Table 4: Overview of pivotal trial data for Teflaro in ABSSSI
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.